S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:REUN

Reunion Neuroscience (REUN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.12
$1.12
50-Day Range
$1.11
$1.13
52-Week Range
$0.63
$5.07
Volume
N/A
Average Volume
210,209 shs
Market Capitalization
$13.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

REUN stock logo

About Reunion Neuroscience (NASDAQ:REUN) Stock

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.


REUN Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
See More Headlines
Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

REUN Company Calendar

Today
10/01/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Health services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REUN
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+1,283.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-36,690,000.00
Pretax Margin
-2,583.10%

Debt

Sales & Book Value

Annual Sales
$3.88 million
Book Value
$1.37 per share

Miscellaneous

Free Float
N/A
Market Cap
$13.13 million
Optionable
Not Optionable
Beta
2.29
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Hannan Fleiman (Age 42)
    Co-Founder & Non-Independent Director
    Comp: $214.69k
  • Dr. Nathan Bryson B.Sc. (Age 59)
    Ph.D., Chief Science Officer
    Comp: $312.47k
  • Mr. Gregory T. Mayes Esq. (Age 54)
    J.D., Pres, CEO & Director
  • Mr. Edward F. Smith CPA (Age 52)
    Chief Financial Officer
  • Mr. Curtis Weber
    Gen. Counsel
  • Mr. Stephan Cote
    Head of Quality
  • Dr. Robert Alexander M.D.
    Chief Medical Officer & Sr. Advisor













REUN Stock - Frequently Asked Questions

Should I buy or sell Reunion Neuroscience stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reunion Neuroscience in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REUN shares.
View REUN analyst ratings
or view top-rated stocks.

What is Reunion Neuroscience's stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month price targets for Reunion Neuroscience's shares. Their REUN share price forecasts range from $11.00 to $20.00. On average, they predict the company's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,283.9% from the stock's current price.
View analysts price targets for REUN
or view top-rated stocks among Wall Street analysts.

What is Reunion Neuroscience's stock symbol?

Reunion Neuroscience trades on the NASDAQ under the ticker symbol "REUN."

What is Reunion Neuroscience's stock price today?

One share of REUN stock can currently be purchased for approximately $1.12.

How much money does Reunion Neuroscience make?

Reunion Neuroscience (NASDAQ:REUN) has a market capitalization of $13.13 million and generates $3.88 million in revenue each year.

How can I contact Reunion Neuroscience?

Reunion Neuroscience's mailing address is 30 DUNCAN STREET SUITE 400, TORONTO A6, M5V 2C3. The official website for the company is www.reunionneuro.com. The company can be reached via phone at 1-833-222-0084, via email at investors@fieldtriphealth.com, or via fax at 1-855-933-1211.

This page (NASDAQ:REUN) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -